Physicians' lifestyle advice on primary and secondary CVD prevention in Germany: A comparison between the STAAB cohort study and the German subset of EUROASPIRE IV

Theresa Tiffe^{1,2}, Caroline Morbach^{1,3}, Carolin Malsch^{1,2}, Götz Gelbrich^{1,2}, Valerie Wahl^{1, 2}, Martin Wagner^{1,2}, Kornelia Kotseva⁴, David Wood⁴, Rainer Leyh^{1,5}, Georg Ertl¹, Wolfgang Karmann⁶, Stefan Störk^{1,3*}, Peter U. Heuschmann^{1,2,7*}; on behalf of the STAAB Consortium

1 Comprehensive Heart Failure Center, University Hospital and University of Würzburg, Germany

2 Institute of Clinical Epidemiology and Biometry, University of Würzburg, Germany

3 Dept. of Medicine I, University Hospital Würzburg, Germany

4 Dept. of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London, London, UK

5 Dept. of Cardiovascular Surgery, University Hospital Würzburg, Würzburg, Germany

6 Dept. of Medicine, Klinik Kitzinger Land, Kitzingen, Germany

7 Clinical Trial Center, University Hospital Würzburg

* contributed equally

Corresponding author:

Prof. Dr. Peter U. Heuschmann

Institute of Clinical Epidemiology and Biometry

Josef-Schneider-Str. 2 / House D7

97080 Würzburg, Germany

Tel: +49 (931) 201 47308

email: peter.heuschmann@uni-wuerzburg.de

Parts of the results have been presented at the "Herztage" of the Autumn Conference of the German Society of Cardiology, Berlin 2018, Germany.

Abstract

Background: We assessed prevalence and determinants on appropriate physician-led lifestyle advice (PLA) in a population-based sample of individuals without cardiovascular disease (CVD) compared to a sample of CVD patients.

Methods: PLA were assessed via questionnaire in a subsample of the population-based *Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression* (STAAB) cohort free of CVD (primary prevention sample), and the German subset of the 4th EUROASPIRE Survey (EA-IV) comprising CVD patients (secondary prevention sample). “PLA” was fulfilled if the participant reported on having ever been told by a physician to: stop smoking (current/former smokers), reduce weight (overweight/obese participants), increase physical activity (physically inactive participants), or keep a healthy diet (all participants). Factors associated with receiving at least 50% of PLA were identified using logistic regression: including in the first step age, sex, education, hypertension (HT), diabetes mellitus (DM), hyperlipidemia (HPL) and, in a second step, also lifestyle factors such as smoking, BMI >25 kg/m², and physical inactivity.

Results: Information on PLA was available in 665 STAAB participants (55±11; 55% females) and in 536 EA-IV patients (67±9; 18% females). Except for smoking, appropriate PLA was more frequently given in the secondary compared to the primary prevention sample. Determinants associated with appropriate PLA in primary prevention were: DM (OR 5.61; 95%CI 2.40-13.08), HPL (OR 2.92; 95%CI 2.03-4.21), and HT (OR 1.85; 95%CI 1.29-2.66); and in secondary prevention: age (OR per year 0.95; 95% CI 0.93-0.98), and DM (OR 2.43; 95%CI 1.43-4.12).

Conclusions: In primary prevention, PLA was mainly determined by the presence of vascular risk factors, whereas in secondary prevention the level of PLA was higher in general, but the association between CVD risk factors and PLA was less pronounced.

Key words: cardiovascular risk factors, primary prevention, secondary prevention, population-based, primary care, lifestyle advice

Introduction

Implementing and maintaining good lifestyle habits constitutes a central recommendation of guidelines on primary and secondary prevention of cardiovascular disease (CVD).^{1, 2} CVD prevention aims to improve quality of life and life expectancy, both in primary and secondary care.³ The strong relationship between the risk of developing CVD and behavioural risk factors including lack of regular physical activity, smoking, and poor diet, is well described.³ Favourable adoption of lifestyle factors was shown to significantly reduced incident and recurrent CVD events as well as CVD mortality risk.³⁻⁸

The EUROASPIRE (EUROpean Action on Secondary and Primary prevention In order to Reduce Events) surveys iteratively report on the magnitude of and secular trends regarding lifestyle and risk factor management according to European guidelines in individuals at high CVD risk or with established CVD.⁶ For example, in EUROASPIRE IV (EA-IV), only half of coronary patients were advised to attend a CVD prevention and rehabilitation program.^{6, 9, 10} Time trends in lifestyle risk factors of the EUROASPIRE II, III and IV surveys of 9 European countries over a period of 14 years showed that the prevalence of adverse lifestyle factors such as obesity and central obesity increased by 7% and 6%, respectively, and one out of five coronary patients still smoked at the time of evaluation, 6 months to three years after a cardiac event.¹¹

To positively impact on cardiovascular risk, a multidisciplinary approach is advocated emphasizing lifestyle modification and risk factor management in both primary and secondary prevention.^{6, 12, 13} The importance of the treating physician promoting a healthy lifestyle in routine care has been underscored by various reports.^{6, 14, 15} Treating physicians play an important role in addressing good lifestyle habits and supporting patients to implement lifestyle into their everyday life using health education, health promotion, and behavioral counselling in primary and secondary prevention.^{13, 16, 15}

However, little is known about the frequency of appropriate physician-led lifestyle advices (PLA) according to recent CVD prevention guidelines as well as factors determining, which patient will receive PLA in different health care settings. Therefore, we compared the prevalence and determinants of PLA between participants from the general population without CVD (i.e. primary prevention setting) and CVD patients (i.e., secondary prevention setting).

Methods

Primary prevention

Information regarding primary prevention sample was derived from a subset of the population-based *Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression* (STAAB) cohort study. STAAB aims to examine the prevalence and natural course of early heart failure stages in a randomly selected representative sample of 5000 inhabitants of the City of Würzburg, aged 30-79 years. The study design and rationale have been published in detail previously.¹⁷ For the current analysis, we excluded participants with established cardiovascular disease (CVD) defined by a self-reported history of coronary artery disease, peripheral artery disease, or stroke.

Data collection

Information on sociodemographic status (sex, age, education), smoking, recommended lifestyle advice given by physicians, and physical activity, was obtained via face-to-face interview. Weight, height, and blood pressure were obtained applying standard operative procedures. Blood pressure was measured on the dominant upper arm up to three times in sitting position. Self-reported history of CVD and cardiovascular risk factors (diabetes, high blood pressure, hyperlipidemia) were obtained by study physicians. Blood samples were collected in fasting participants. All examinations were performed according to standardized operation procedures.

Secondary prevention setting

Information regarding secondary prevention sample was derived from the German subset of the “hospital-arm” of the EA-IV Survey recruited from the University Hospital Würzburg and the Dept. of Medicine, Klinik Kitzinger Land. Study subjects were approached six months to three years after hospitalization for a coronary event (index). EA-IV was conducted between 2012 and 2013 in 24 European countries to investigate the quality of cardiovascular risk factor control and guideline implementation in clinical practice.⁹ Patients were aged between 19 and 79 years and suffered from coronary heart disease (acute myocardial infarction, unstable angina, percutaneous coronary intervention, or coronary bypass grafting). The study design and rationale of the German subset of EA-IV have been published in detail previously.¹⁸

Data collection

Medical records were reviewed to collect information about details of the index event. Sociodemographic status (sex, age and education), self-reported CVD risk factors (diabetes, high blood pressure, hyperlipidemia) and information on smoking were obtained in a personal patient interview 6 to 36 months after hospitalization for the index event. Weight, height, and blood pressure were assessed by physical examination. Blood pressure was measured twice on the dominant upper arm in sitting position. Provided lifestyle advice was collected by self-administered questionnaire. All examinations were performed according to EA-IV standards at the study visit.

For both prevention samples, body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. Physical activity (≥ 150 min/week of moderate activity or ≥ 75 min/week of strenuous activity) was operationalized by the International Physical Activity Questionnaire (IPAQ).¹⁹

Due to the differences in the assessment of the individual’s educational level in STAAB (school leave qualification) and EA-IV (vocational qualification), we harmonized the educational level as follows: no

formal schooling, less than primary schooling, primary school completed, secondary school completed, high school completed, intermediate between secondary level and university (e.g. technical training) to low school-leaving qualification. College/University completed and postgraduate degree were allocated to graduate of a higher school.

Definition of recommended lifestyle advice

Physician-led appropriate lifestyle advice (PLA) was defined according to recent European Guidelines on CVD Prevention in Clinical Practice (version 2016)³ if the study participant reported on having ever been told by a physician: to stop smoking in current/former smoking participants; to reduce weight in participants with a BMI >25 kg/m²; to increase physical activity in participants with less than <150 min/week moderate activity; or to keep a healthy diet was recommended for all participants. The rate of adequately received lifestyle advices was calculated as the percentage of lifestyle advices divided by the number of all lifestyle advices a patient was potentially eligible for. For example, if a patient met criteria for three, but had received only two lifestyle advices, then he was considered having received 67% of adequate lifestyle advices.

Determinants for receiving lifestyle advice

A priori, we identified a set of covariables potentially related to receiving PLA including sociodemographic factors (age, sex, education), self-reported CVD risk factors (diabetes, high blood pressure, hyperlipidaemia), and lifestyle risk factors (smoking, overweight, physical inactivity).^{6, 20-22}

Data analysis

For categorical variables, we reported proportions (%). For univariable analysis, χ^2 -test for categorical and binary variables or Fisher's exact were used, as appropriate. Percentage of PLA was calculated and determinants of receiving at least 50% of PLA in either study sample were identified. We calculated in a

sensitivity analysis proportions for PLA in STAAB participants at “high CVD risk” according to the recent definition for EA-IV patients from the “primary care arm”. This definition based on the prescription of blood pressure lowering and/or lipid-lowering medication, and/or diabetes on treatment (diet or medications).²³ In a first multivariable logistic regression analysis we calculated odds ratios (OR) with 95% confidence intervals (CI) to assess whether sociodemographic status or self-reported CVD risk factors predicted the chance to receive $\geq 50\%$ of PLA. In a second model, we adjusted also for CVD lifestyle risk factors. P-values < 0.05 were considered statistically significant. Analyses were performed with IBM SPSS Statistics 23 (IBM® SPSS® Statistics Version 23).

Ethics and data protection

For the STAAB cohort study and the EA-IV study, approvals of the Ethics Committee of the Medical Faculty of the University of Würzburg (votes 98/13 and 58/12, respectively) and the data protection officer of the University of Würzburg (J-117.605-09/13) were obtained. All participants provided written informed consent prior to study examinations.

Results

Characteristics of the study participants in primary and secondary prevention

For the primary prevention sample, we assessed recommended lifestyle advice in a subsample of 707 participants via face-to-face interview. All 707 participants received and completed the lifestyle questionnaire. Of those, 42 (5.9%) reported a history of CVD. Therefore, 665 participants (mean age 54.9 ± 11.4 years; 55.3% women) were included in the present analyses.

For the secondary prevention sample, recommended lifestyle advice was assessed in the entire 536 participants (mean age 67.4 ± 8.9 years; 17.7% women) from the German subsample of the EA-IV survey. Characteristics of both study populations are shown in Table 1.

In general, frequency of receiving PLA was higher in patients from the secondary compared to the primary prevention sample; “keep healthy diet”: EA-IV 73.1%, STAAB 43.9% ($p < 0.001$); “reduce weight”: EA-IV 69.2%, STAAB 43.8% ($p < 0.001$); “increase physical activity”: EA-IV: 71.4%, STAAB: 52.1% ($p < 0.01$), except for the advice for smoking cessation: STAAB: 44.0%, EA-IV: 36.7% ($p = 0.08$). According to the recent definition for EA-IV patients at high CVD risk from the “primary care arm” we identified 200 (31.0%) STAAB participants at high CVD risk with higher proportions for PLA (reduce weight: 56.4%; increase physical activity: 54.7%), except for smoking with 42.7% compared to the entire STAAB primary prevention sample.

Significantly higher proportions for receiving $\geq 50\%$ of PLA were observed in participants with self-reported hypertension (63.5%, $p < 0.001$), high LDL-C levels (67.6%, $p < 0.001$) and diabetes mellitus (85.4%, $p < 0.001$) in the primary prevention sample.

In the secondary prevention sample, patients with self-reported diabetes mellitus (84.4%, $p = 0.01$) more frequently received $\geq 50\%$ PLA; no statistically significant differences were observed for the other risk factors. Age, sex and education were not associated with receiving $\geq 50\%$ PLA in both primary and secondary prevention settings (Table 1).

Determinants for receiving $\geq 50\%$ appropriate lifestyle advices

In multivariable analyses, the chance for receiving $\geq 50\%$ PLA in primary prevention was significantly higher in patients with self-reported diabetes mellitus (OR 5.61; 95%CI 2.40-13.08), hyperlipidemia (OR 2.92; 95%CI 2.03-4.21), and hypertension (OR 1.85; 95%CI 1.29-2.66). In secondary prevention setting, patients with diabetes mellitus was independently associated with a higher chance for receiving $\geq 50\%$ PLA (OR 2.43; 95%CI 1.43-4.12), whereas a decrease of receiving $\geq 50\%$ PLA with advancing age (OR per year 0.95; 95% CI 0.93-0.98) was observed in the total secondary prevention sample (Table 3a).

Adding lifestyle risk factors as potential determinants to the multivariable models did not substantially alter these results, except for BMI $>25 \text{ kg/m}^2$ in the primary prevention sample (OR 1.80, 95%CI 1.22; 2.65) [Table 3b]. A relevant number of missing values occurred in the second multivariable model (18.2% in STAAB and 28.7% in EA-IV) therefore we compared the distribution of the dependent as well as the independent variables between the total data set and the selected data set, and observed no variations. Consequently, we assume that the selected data set is representative for the whole sample and that values are missing at random (Supplement Table 3 a-b).

Discussion

Our study assessed the prevalence and determinants for receiving PLA recommended in current clinical guidelines for CVD prevention in primary and secondary prevention settings. We observed that individuals in secondary prevention setting received significantly more often PLA compared to individuals without established CVD, except for smoking cessation. In the primary prevention setting, established CVD risk factors such as hypertension, hyperlipidemia and diabetes mellitus were strongly related to a higher chance of receiving $\geq 50\%$ PLA. In secondary prevention settings, the only association between CVD risk factors and PLA was found for diabetes mellitus. In addition, we observe a decrease of PLA with increasing age in secondary prevention.

Prevalence of adequate lifestyle advice in primary prevention samples

A direct comparison of lifestyle risk factor management with previous studies is limited due to varying target populations as well as due to differences in the assessment of lifestyle risk factors. In addition, most of the previous studies on this topic were conducted in primary care settings in patients with high CVD risk. The “primary care arm” from the EA-IV survey included 4579 patients at high risk of CVD in 14 European countries (mean age 58.8 years, 57.8% women) observed more frequently lifestyle advice (smoking cessation: 73.5%, reduce weight: 65.2% and increase physical activity: 59.0%) compared to the

entire STAAB primary prevention sample with 44.0%, 43.8% and 52.1%, respectively.²³ In addition, we observed still lower proportions in the predefined STAAB participants at high CVD risk. The higher recommendation rates in EA-IV could result from the fact, that also recommendations made by other healthcare professionals were considered. Another international cross-sectional observational study from the European Practice Assessment of Cardiovascular Risk Management (EPA Cardio) project²⁴ in 9 European countries including 3723 individuals at high risk of CVD (mean age 66 years, 29.5% women; without established diabetes) from 268 general practices recorded lifestyle counselling by general practitioners documented within the medical records within the last 15 month.²⁵ This study also observed higher proportions of advice for smoking cessation (65.5%) compared to STAAB, but lower proportions for physical activity advice (38.8%) were reported.²⁵ Advice for a healthy diet was comparable with our findings (EPA Cardio: 42.9%; STAAB: 43.8 %).²⁵

There may be a stronger tendency of physicians to recommend lifestyle advice in patients at high CVD risk compared to individuals with lower CVD risk as were present in the healthier STAAB subsample with less comorbidity, considering that the STAAB sample with a mean age 54.9 was overall younger than patients from the EA-IV survey (mean age 58.8 years) and EPA cardio project (mean age 66).^{23, 25}

Prevalence of adequate lifestyle advice in secondary prevention samples

The EUROASPIRE “hospital arm” from the EA-IV survey with 7998 coronary patients (mean age at interview 64.0 years [$\pm$ SD 11.3], 24.4% women) observed higher rates of recommendation over all forms of advice in smoking cessation. Having received verbal advice was reported in 88.5%, written information material in 42.6% and attended to a smoking cessation clinic in 18.6% which was more frequently when compared to the German EA-IV subsample with 34.2%, 13.1% and 8.2%, respectively. Similarly, higher rates of smoking cessation advice compared to our data were observed in the New Zealand SNAPSHOT ACS study, a large prospective audit of 2299 patients (mean age 69 years [$\pm$ SD 1.3], 35% women)

hospitalized with an acute coronary syndrome.²⁶ In this survey, almost two-thirds of smoking patients received the advice to stop smoking. The higher recommendation rates regarding smoking advice in current studies underlines the insufficient recommendation to stop smoking advice in our German secondary prevention sample. The world-wide considerable potential of the improvement of healthy lifestyle in secondary prevention is also emphasized by the Prospective Urban Rural Epidemiology (PURE) cohort study in 153,996 adults, aged 35-70 years from 628 urban and rural communities of whom 7519 individuals reported CVD or stroke. From a total of three investigated healthy lifestyle behaviours (healthy eating, smoking cessation and physical activity) only 4.3% (95%CI 3.1-5.8%) of the participants had received all healthy life style behaviours.²⁷

Comparison of lifestyle advice in primary and secondary prevention setting

We found PLA more frequently given in secondary compared to primary prevention sample, except for smoking. To the best of our knowledge, no comparable data was found with regard to directly analyzing recommended lifestyle advice between primary and secondary prevention settings based on comparable data collection and risk factor definitions. However, there are few studies focussing on differences in frequency of healthy lifestyle behaviours in patients using comparable data. A cross-sectional study by Wang et al. from the PURE-China study compared healthy lifestyle behaviours in individuals with and without CVD or stroke among 40,490 participants. Four healthy lifestyle habits were assessed (smoking cessation in current/former smokers, physical activity, healthy diet, self-reported alcohol consumption) and participants with CVD, stroke and diabetes were allocated to disease group, whereas participants without report any disease were allocated to control group. Overall, they reported significantly higher rates of smoking cessation, quit drinking alcoholic products in participants with disease compared to the healthy control group, whereas equal proportions were found for physical activity, and dietary intake was depended from income and rural vs. urban communities. Further, less than 10% had all four healthy lifestyle habits and the adoption of two or more lifestyle habits, increased with the number of CVD

events.²⁸ In line with the present PURE study, there is evidence, that participants with CVD might be aware of their CVD related mortality and recurrent events and, therefore, more likely to follow healthy lifestyle habits.^{29, 30} Our result showed that also at the physician's side, lifestyle advice in secondary prevention settings are more frequently recommend compared to primary prevention. However, considering that in our primary and secondary prevention samples, still a substantial number of patients are overweight/obese or physically inactive, there is a clear demand of improvement of increasing physicians' lifestyle advice in both, primary and secondary prevention settings.

Determinants for adequate lifestyle advice

Primary prevention setting

CVD risk factors (self-reported blood pressure, high LDL-C levels and diabetes) were strongly associated with a higher chance of receiving $\geq 50\%$ PLA. A study from the EPA cardio project focused on determinants regarding recording rates of single lifestyle advice (stop smoking, diet and physical activity) from medical records in participants with high cardiovascular risk.²⁵ A healthy diet was less often recorded with increasing age, but more often recorded in women as well as the advice for increasing physical activity compared to men. Furthermore, with increasing number of risk factors including CVD risk factors (elevated blood pressure, high total cholesterol and raised blood glucose) such as lifestyle risk factors (weight or BMI, physical activity and smoking), the documentation rates increased for all three lifestyle advice.²⁵ This is in line with our finding from the STAAB primary prevention sample, where CVD risk factors also strongly related to receive PLA.

Secondary prevention setting

We observed a lower probability of PLA with increasing age in our study. This is in line with results from previous studies. The SNAPSHOT ACS study assessed optimal preventive care defined by the patients having received at least one of exercise or healthy diet advice or advice for smoking cessation.³¹ The

probability of receiving in-hospital lifestyle advice was significantly lower (p 0.012) in patients being older than 70 years compared to younger ones.³¹ The Survey of Health, Ageing and Retirement in Europe (SHARE) also showed improvable behavioural lifestyle habits in the elderly.³² However, as older patients benefit significantly from lifestyle interventions, the reasons for the lower frequency of adequate lifestyle recommendations by physicians in older age groups should be identified and amended. Individual comorbid conditions and the ability to adopt new lifestyle habits might be specifically considered in this patient group, e.g. by recommending light to moderate physical activities instead of reaching official recommended targets.^{33, 34} A recent study examined the relationship between health beliefs and behavioural changes among younger (50-69 years) and older adults (70-89 years) and pointing out that compared to younger participants, older participants were more confused about healthy eating habits or how to stay healthy in general.³⁵ This highlights that lifestyle interventions should be adapted according to the needs of older aged individuals including close guidance to avoid confusion with regard to health behaviours.

Furthermore, diabetes was the only cardiovascular risk factor, associated with a higher chance for lifestyle recommendations $\geq 50\%$ in our secondary prevention sample. There is evidence, that especially patients with diabetes do not achieve treatment targets for secondary prevention. In addition, health care providers might specifically focus on this high-risk population because of their higher risk of all-cause and CVD-related mortality. For example, the EA-III survey assessed determinants for risk factor control (failing recommended targets in total cholesterol <4.5 mmol/l, blood pressure $<149/90$ mmHg and non-smoking) in coronary subjects and observed a three times higher risk for patients diagnosed with diabetes to failing secondary prevention targets compared to non-diabetics.³⁶ The National Health Interview Survey (NHIS) examined the epidemic of diabetes in 22,305 subjects aged ≥ 18 years from the United States. In male patients with diabetes, they observed a 1.56 times higher risk of death from all-cause, a 1.72 times higher risk from heart disease, a 1.48 times higher risk from cerebrovascular disease

and 1.67 times risk higher from CVD than subjects without diabetes, respectively with no difference from female patients with diabetes.³⁷ Further studies reported an increased mortality especially in patients with ACS and the Health Professional Follow up study shows that an overall healthy lifestyle is significantly associated with a 27% ($p < 0.001$) lower risk of CVD mortality in patients with type 2 diabetes.^{38, 39, 40, 41}

Limitations

There might be a selection bias of invited participants. Healthier subjects from the primary prevention setting might tend to participate more frequently in the study, whereas present secondary prevention setting might represent a “healthier” CVD population, which survived long enough after index event and therefore able to undergo physical examinations and interviews. Therefore, our results might overestimate the level of PLA. The samples were derived from our local Würzburg population, thus, our results may not be generalizable to other German regions due to different risk profiles, age structure, and distribution of lifestyle factors. We did not assess reasons for the individual lifestyle recommendations by the physician. Furthermore, the prevalence of self-reported lifestyle recommendations could be subject to recall bias. Due to the different assessment of the school-leave certificate in the primary and secondary sample with the resulting harmonization, a misclassification regarding this marker of socioeconomic status may have occurred. Finally, the multivariable model only accounted for a number of a priori defined factors leaving room for residual confounding.

Conclusion

The present study demonstrates opportunities to improve the implementation of guideline-recommended lifestyle advice, in both primary and secondary prevention settings. Whereas presence of cardiovascular risk factors was strongly associated with the probability of receiving at least 50% of adequate PLA in primary prevention, such associations were absent or less pronounced in secondary prevention. This

327 might indicate that physicians are more focused on clinical risk factors instead of lifestyle risk factors
328 when recommending lifestyle advice in the general population. In our secondary prevention sample,
329 older patients with CVD had a lower chance of receiving PLA. Therefore, a closer guidance of lifestyle
330 counselling with respect to the needs and quality of life should be considered.

331

Acknowledgements

On behalf of the STAAB consortium: S. Frantz (Dept. of Medicine I, Div. of Cardiology, University Hospital Würzburg); C. Maack (Comprehensive Heart Failure Center, University Hospital and University of Würzburg); M. Fassnacht (Dept. of Medicine I, Div. of Endocrinology, University Hospital Würzburg); C. Wanner (Dept. of Medicine I, Div. of Nephrology, University Hospital Würzburg); J. Volkmann (Dept. of Neurology, University Hospital Würzburg); J. Deckert (Dept. of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital Würzburg); H. Faller (Dept. of Medical Psychology, University of Würzburg); R. Jahns (Interdisciplinary Bank of Biomaterials and Data Würzburg, University Hospital Würzburg).

We greatly appreciate the time of all STAAB participants and their willingness to provide data to the study. We also thank the Mayor of the City of Würzburg and the local registration office for their kind and sustained support of our study. Further, we thank the entire study team including F. Eichner, V. Ceijka, M. Mattern, C. Morbach, M. Breunig, study nurses, technicians, data managers, and students for their efforts on the STAAB study. We also thank Rudy Meijer from Meijer Medical Ultrasound, Vorschooten, The Netherlands, for external training and certification in vessel ultrasound as well as M. Ertl, G. Fette, F. Puppe from the CHFC DataWarehouse, Institute of Informatics VI, University of Würzburg. Further, we thank the participants of the German EUROASPIRE IV survey for providing their data, as well as we thank all study coordinators, physicians, nurses, assistants, and students of the recruiting centers for their time and effort on data collection. We gratefully acknowledge the support of A. Adamska (Dept. of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London, UK) for the administrative assistance and M. Glemot and M. Konte (EURObservationalResearch Programme, European Heart House, Sophia-Antipolis, France) for the data management assistance within the EUROASPIRE IV survey. EUROASPIRE survey was carried out under the hospices of European Society of Cardiology EURObservational Research Programme.

We also thank the Divisions of Nephrology (C. Wanner) and Endocrinology (B. Allolio[†], M. Fassnacht), University Hospital Würzburg, and the Interdisciplinary Bank of Biomaterials and Data Würzburg (R. Jahns), University of Würzburg. The content of this publication is within responsibility of the author.

Funding

The STAAB cohort study is supported by the German Ministry of Research and Education within the Comprehensive Heart Failure Centre Würzburg (BMBF 01EO1004 and 01EO1504).

Data collection at the German EUROASPIRE IV study center was supported by the German Ministry of Education and Research (BMBF) within the Comprehensive Heart Failure Center Würzburg (BMBF 01EO1004). This publication was funded by the German Research Foundation (DFG) and the University of Würzburg in the funding programme Open Access Publishing.

The EUROASPIRE IV survey was carried out under the auspices of the European Society of Cardiology, EURObservational Research Programme. The survey was supported through unrestricted research grants to the European Society of Cardiology from AstraZeneca, Bristol-Myers Squibb/ Emea Sarl, GlaxoSmithKline, F. Hoffman-La Roche (Gold Sponsors), Merck, Sharp & Dohme and Amgen (Bronze Sponsors). The sponsors of the EUROASPIRE surveys had no role in the design, data collection, data analysis, data interpretation, decision to publish, or writing the manuscript.

Declaration of conflicting interests

CMo reports a speakers honorarium from Amgen, a travel grant from Thermo Fisher, Orion Pharma, and Alnylam, and participation in Scientific Advisory and Patient Eligibility Boards sponsored by AKCEA, Alnylam, and EBR Systems outside the submitted work. **SS** reports research grants from the German Ministry of Education and Research, European Union, University Hospital Würzburg; participation in Data Safety Monitoring and Event Adjudication Boards in trials sponsored by ROCHE and MEDTRONIC;

principal investigator in trials (co-)sponsored by BOEHRINGER, NOVARTIS, BAYER, LUNDBECK; speaker honaria by BOEHRINGER, SERVIER, NOVARTIS, ASTRA-ZENECA, PFIZER, BAYER. **PUH** reports research grants from the German Ministry of Research and Education, German Research Foundation, European Union, Charité, Berlin Chamber of Physicians, German Parkinson Society, University Hospital Würzburg, Robert-Koch-Institute, German Heart Foundation, Federal Joint Committee (G-BA) within the Innovationfond, Charité–Universitätsmedizin Berlin (within MonDAFIS; supported by an unrestricted research grant to the Charité from Bayer), University Göttingen (within FIND-AF-randomized; supported by an unrestricted research grant to the University Göttingen from Boehringer-Ingelheim), and University Hospital Heidelberg (within RASUNOA-prime; supported by an unrestricted research grant to the University Hospital Heidelberg from Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo), outside submitted work. GE reports research grants from the German Ministry of Education and Research (BMBF), Lundbeck non-financial support, Bayer grants, and Novartis grants and personal fees. KK reports research grants from the European Society of Cardiology related the submitted work; consultancy fees from Amgen, outside the submitted work.

Authors' contributions

TT contributed to conception and design of the STAAB cohort study and drafted the manuscript. CMO contributed to data acquisition and interpretation. CM contributed to analysis. GG contributed to study conception, analysis, and interpretation. MW contributed to study conception and data acquisition. SS and PUH designed the STAAB cohort study and the German subset of EUROASPIRE IV, acquired funding and drafted the manuscript. VW, KK, DW, GE, RL and WK contributed to data acquisition of the EA-IV survey. All authors critically revised and approved the final manuscript.

395   **References**

- 396   1.   Kok G, van den Borne B and Mullen PD. Effectiveness of health education and health promotion:
397 meta-analyses of effect studies and determinants of effectiveness. *Patient Educ Couns*. 1997; 30: 19-27.
- 398   2.   Steptoe A, Doherty S, Rink E, Kerry S, Kendrick T and Hilton S. Behavioural counselling in general
399 practice for the promotion of healthy behaviour among adults at increased risk of coronary heart
400 disease: randomised trial. *BMJ (Clinical research ed)*. 1999; 319: 943-7; discussion 7-8.
- 401   3.   Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease
402 prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other
403 Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10
404 societies and by invited experts): Developed with the special contribution of the European Association
405 for Cardiovascular Prevention & Rehabilitation (EACPR). *European journal of preventive cardiology*. 2016.
- 406   4.   Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS and Yusuf S. Association of diet, exercise, and
407 smoking modification with risk of early cardiovascular events after acute coronary syndromes.
408 *Circulation*. 2010; 121: 750-8.
- 409   5.   Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with
410 myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet (London,
411 England)*. 2004; 364: 937-52.
- 412   6.   Kotseva K. The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention.
413 *Cardiovascular diagnosis and therapy*. 2017; 7: 633-9.
- 414   7.   Notara V, Panagiotakos DB and Pitsavos CE. Secondary prevention of acute coronary syndrome.
415 Socio-economic and lifestyle determinants: a literature review. *Central European journal of public health*.
416 2014; 22: 175-82.
- 417   8.   Hulsege G, Looman M, Smit HA, Daviglus ML, van der Schouw YT and Verschuren WM. Lifestyle
418 Changes in Young Adulthood and Middle Age and Risk of Cardiovascular Disease and All-Cause Mortality:
419 The Doetinchem Cohort Study. *Journal of the American Heart Association*. 2016; 5.
- 420   9.   Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: A European Society of Cardiology
421 survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European
422 countries. *European journal of preventive cardiology*. 2015. **Eur J Prev Cardiology** 2016; 23: 636–648
- 423   10.   Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III. Management of cardiovascular risk
424 factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European
425 countries. *European journal of cardiovascular prevention and rehabilitation : official journal of the
426 European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac
427 Rehabilitation and Exercise Physiology*. 2010; 17: 530-40.
- 428   11.   Kotseva K, De Bacquer D, Jennings C, et al. Time Trends in Lifestyle, Risk Factor Control, and Use
429 of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3
430 EUROASPIRE Surveys, 1999-2013. *Global heart*. 2017; 12: 315-22.e3.
- 431   12.   Kromhout D, Menotti A, Kesteloot H and Sans S. Prevention of coronary heart disease by diet
432 and lifestyle: evidence from prospective cross-cultural, cohort, and intervention studies. *Circulation*.
433 2002; 105: 893-8.
- 434   13.   Goldstein MG, Whitlock EP and DePue J. Multiple behavioral risk factor interventions in primary
435 care. Summary of research evidence. *American journal of preventive medicine*. 2004; 27: 61-79.
- 436   14.   Wallace PG, Brennan PJ and Haines AP. Are general practitioners doing enough to promote
437 healthy lifestyle? Findings of the Medical Research Council's general practice research framework study
438 on lifestyle and health. *British medical journal (Clinical research ed)*. 1987; 294: 940-2.
- 439   15.   Franco M, Cooper RS, Bilal U and Fuster V. Challenges and Opportunities for Cardiovascular
440 Disease Prevention. *The American journal of medicine*. 2011; 124: 95-102.

16. Steptoe A, Kerry S, Rink E and Hilton S. The impact of behavioral counseling on stage of change in fat intake, physical activity, and cigarette smoking in adults at increased risk of coronary heart disease. *American journal of public health*. 2001; 91: 265-9.
17. Wagner M, Tiffe T, Morbach C, Gelbrich G, Stork S and Heuschmann PU. Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression - design and rationale of the STAAB cohort study. *European journal of preventive cardiology*. 2016.
18. Wagner M, Wanner C, Schich M, et al. Patient's and physician's awareness of kidney disease in coronary heart disease patients – a cross-sectional analysis of the German subset of the EUROASPIRE IV survey. *BMC Nephrology*. 2017; 18: 321.
19. Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12-country reliability and validity. *Medicine and science in sports and exercise*. 2003; 35: 1381-95.
20. Brobeck E, Bergh H, Odencrants S and Hildingh C. Lifestyle advice and lifestyle change: to what degree does lifestyle advice of healthcare professionals reach the population, focusing on gender, age and education? *Scandinavian journal of caring sciences*. 2015; 29: 118-25.
21. De Smedt D, De Bacquer D, De Sutter J, et al. The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. *International Journal of Cardiology*. 2016; 209: 284-90.
22. Kotseva K, Wood D and De Bacquer D. Determinants of participation and risk factor control according to attendance in cardiac rehabilitation programmes in coronary patients in Europe: EUROASPIRE IV survey. *European journal of preventive cardiology*. 2018: 2047487318781359.
23. Kotseva K, De Bacquer D, De Backer G, et al. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. *European journal of preventive cardiology*. 2016.
24. Wensing M, Ludt S, Campbell S, van Lieshout J, Volbracht E and Grol R. European Practice Assessment of Cardiovascular risk management (EPA Cardio): protocol of an international observational study in primary care. *Implementation science : IS*. 2009; 4: 3.
25. Ludt S, Petek D, Laux G, et al. Recording of risk-factors and lifestyle counselling in patients at high risk for cardiovascular diseases in European primary care. *European journal of preventive cardiology*. 2012; 19: 258-66.
26. Chew DP, French J, Briffa TG, et al. Acute coronary syndrome care across Australia and New Zealand: the SNAPSHOT ACS study. *The Medical journal of Australia*. 2013; 199: 185-91.
27. Teo K, Lear S, Islam S, et al. Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. *Jama*. 2013; 309: 1613-21.
28. Wang C and Li W. Comparison of healthy lifestyle behaviors among individuals with and without cardiovascular diseases from urban and rural areas in China: A cross-sectional study. 2017; 12: e0181981.
29. Fernandez RS, Salamonson Y, Griffiths R, Juergens C and Davidson P. Awareness of risk factors for coronary heart disease following interventional cardiology procedures: a key concern for nursing practice. *International journal of nursing practice*. 2008; 14: 435-42.
30. Wartak SA, Friderici J, Lotfi A, et al. Patients' knowledge of risk and protective factors for cardiovascular disease. *The American journal of cardiology*. 2011; 107: 1480-8.
31. Redfern J, Hyun K, Chew DP, et al. Prescription of secondary prevention medications, lifestyle advice, and referral to rehabilitation among acute coronary syndrome inpatients: results from a large prospective audit in Australia and New Zealand. *Heart (British Cardiac Society)*. 2014; 100: 1281-8.
32. Linardakis M, Smpokos E, Papadaki A, Komninos ID, Tzanakis N and Philalithis A. Prevalence of multiple behavioral risk factors for chronic diseases in adults aged 50+, from eleven European countries - the SHARE study (2004). *Preventive medicine*. 2013; 57: 168-72.

33. Soares-Miranda L, Siscovick DS, Psaty BM, Longstreth WT, Jr. and Mozaffarian D. Physical Activity and Risk of Coronary Heart Disease and Stroke in Older Adults: The Cardiovascular Health Study. *Circulation*. 2016; 133: 147-55.
34. Fraser GE and Shavlik DJ. Risk factors for all-cause and coronary heart disease mortality in the oldest-old. The Adventist Health Study. *Archives of internal medicine*. 1997; 157: 2249-58.
35. Ferrini R, Edelstein S and Barrett-Connor E. The association between health beliefs and health behavior change in older adults. *Preventive medicine*. 1994; 23: 1-5.
36. Cooney MT, Kotseva K, Dudina A, De Backer G, Wood D and Graham I. Determinants of risk factor control in subjects with coronary heart disease: a report from the EUROASPIRE III investigators. *European journal of preventive cardiology*. 2013; 20: 686-91.
37. Liu L, Simon B, Shi J, Mallhi AK and Eisen HJ. Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: Evidence on health outcomes and antidiabetic treatment in United States adults. *World journal of diabetes*. 2016; 7: 449-61.
38. Loudon BL, Gollop ND, Carter PR, Uppal H, Chandran S and Potluri R. Impact of cardiovascular risk factors and disease on length of stay and mortality in patients with acute coronary syndromes. *Int J Cardiol*. 2016; 220: 745-9.
39. Notara V, Panagiotakos DB, Michalopoulou M, et al. Diabetes Mellitus, Hypertension and Hypercholesterolemia in Relation to the 10-Year ACS Prognosis; the GREECS Study. *Current vascular pharmacology*. 2016; 14: 295-301.
40. Liu G, Li Y, Hu Y, et al. Influence of Lifestyle on Incident Cardiovascular Disease and Mortality in Patients With Diabetes Mellitus. *Journal of the American College of Cardiology*. 2018; 71: 2867-76.
41. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. *American journal of epidemiology*. 1984; 119: 837-9.